KURA · Kura Oncology Inc
United States · RS rating 33 · As of 2026-10-14
| Price | 9.61 USD |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 16 / 29 / 39 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 23 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -8.2% |
| Sales growth Q/Q | -16.4% |
| Distance from 52-week high | +29.3% |
| Market cap (USD) | $822.8M |